{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010568","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.672750+00:00","generated_at":"2026-05-24T14:53:47.466380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PURE Bioscience Q2 net sales up 20% YoY to $391K; net loss narrows to $798K","bullets":["Net product sales $391K for fiscal Q2 ended Jan 31, 2025, vs $325K a year ago (+20%).","Net loss $798K vs $1,002K in prior-year quarter; loss per share unchanged at ($0.01).","SG&A expenses fell $194K due to reductions in personnel, professional fees, and stock comp.","Company advanced dairy membrane solutions to full-scale in-plant pilots with a large distribution partner.","Pilot data shows benefits in water/energy savings, fouling removal, and reduced downtime for dairy ops."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010568","json":"https://secwatch.observer/filing/0001493152-25-010568.json","markdown":"https://secwatch.observer/filing/0001493152-25-010568.md","text":"https://secwatch.observer/filing/0001493152-25-010568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315225010568/0001493152-25-010568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315225010568/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:53:47.466380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}